ArticleProceedings of the National Academy of Sciences of the United States of America2021

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.

Rosalynd Upton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.